Turan Bayhan1, Şule Ünal2, Eyüp Çırak3, Onur Erdem3, Cemal Akay3, Orhan Gürsel4, İbrahim Eker4, Erdem Karabulut5, Fatma Gümrük2. 1. Department of Pediatric Hematology, Hacettepe University, Ankara 06100, Turkey. Electronic address: turanbayhan@yahoo.com. 2. Department of Pediatric Hematology, Hacettepe University, Ankara 06100, Turkey. 3. Department of Toxicology, Gulhane Military Medical Academy, Ankara 06010, Turkey. 4. Department of Pediatric Hematology, Gulhane Military Medical Academy, Ankara 06010, Turkey. 5. Department of Biostatistics, Hacettepe University, Ankara, Turkey.
Abstract
OBJECTIVES: Iron is taken into enterocytes at the duodenum via apical divalent metal-ion transporter 1 protein. Besides iron, divalent metal-ion transporter 1 also transports other divalent metals. We aimed to investigate blood heavy metal levels in patients with ineffective erythropoiesis. METHODS: Blood levels of heavy metals including Pb, Al, Cd, Cr, Co, Cu, and Zn were measured in patients with thalassemia major (TM), thalassemia intermedia (TI), congenital dyserythropoietic anemia (CDA), and age- and sex-matched healthy controls. RESULTS: Blood samples were obtained from 68 patients (51 patients with TM, 8 with TI, 9 with CDA), and a control group that included 65 volunteers. Patients with TM were found to have lower Al, Pb, and Zn, and higher Cd levels compared with the control group. The patients treated with deferasirox were further analyzed and Pb and Zn levels were found lower compared with the control group. DISCUSSION: Patients with TM had tendency to have elevated levels of plasma cadmium; however, the median level was not at a toxic level. Increased metal-ion transporter 1 activity may cause heavy metal accumulation, but deferasirox chelation may be protective against heavy metals besides iron.
OBJECTIVES:Iron is taken into enterocytes at the duodenum via apical divalent metal-ion transporter 1 protein. Besides iron, divalent metal-ion transporter 1 also transports other divalent metals. We aimed to investigate blood heavy metal levels in patients with ineffective erythropoiesis. METHODS: Blood levels of heavy metals including Pb, Al, Cd, Cr, Co, Cu, and Zn were measured in patients with thalassemia major (TM), thalassemia intermedia (TI), congenital dyserythropoietic anemia (CDA), and age- and sex-matched healthy controls. RESULTS: Blood samples were obtained from 68 patients (51 patients with TM, 8 with TI, 9 with CDA), and a control group that included 65 volunteers. Patients with TM were found to have lower Al, Pb, and Zn, and higher Cd levels compared with the control group. The patients treated with deferasirox were further analyzed and Pb and Zn levels were found lower compared with the control group. DISCUSSION: Patients with TM had tendency to have elevated levels of plasma cadmium; however, the median level was not at a toxic level. Increased metal-ion transporter 1 activity may cause heavy metal accumulation, but deferasirox chelation may be protective against heavy metals besides iron.
Authors: Chao-Hsin Huang; Chih-Wen Wang; Huang-Chi Chen; Hung-Pin Tu; Szu-Chia Chen; Chih-Hsing Hung; Chao-Hung Kuo Journal: Int J Environ Res Public Health Date: 2021-12-24 Impact factor: 3.390
Authors: Michael E Brier; Jessica R Gooding; James M Harrington; Jason P Burgess; Susan L McRitchie; Xiaolan Zhang; Brad H Rovin; Jon B Klein; Jonathan Himmelfarb; Susan J Sumner; Michael L Merchant Journal: Sci Rep Date: 2020-11-19 Impact factor: 4.379